




Corrigendum

The Editorial by Sreeram V Ramagopalan and Michael L Ryan, ‘Will the UK–US pharmaceuticals deal really cause 229,000 excess deaths? A critical appraisal’ (10.57264/cer-2026-0186), included an incorrect competing interest statement when initially published.

The competing interest statement appeared as:

The authors have no financial and/or nonfinancial competing interests or relevant affiliations with any organization/entity to declare that are relevant to the subject matter or materials discussed in this manuscript. This includes employment, grants or research funding, consultancies, membership on scientific or other advisory boards, honoraria, stock ownership or options, paid expert testimony, patents received or pending, or royalties.

The updated and accurate competing interest statement is:

SV Ramagopalan is VP Early Commercial Strategy at FingerPost Consulting, a company which advises pharmaceutical and biotechnology companies on market access and pricing. Between 2024 and 2025 he was a partner at Lane Clark and Peacock LLP (LCP), a consultancy whose Health Analytics practice advises pharmaceutical and biotechnology companies on reimbursement and market access. ML Ryan is founder and CEO of Koios Enterprises & Consulting, and a member of the board of directors of Coherus Oncology, a biopharmaceutical company. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

The authors and editors of the *Journal of Comparative Effectiveness Research* would like to apologize for any inconvenience or confusion this may have caused our readers.